Acceleware’s Multi-Core Image Reconstruction Solution Adopted by Major Pharmaceutical Company
CALGARY, Alberta – June 3, 2008 – Acceleware Corp. (TSX-V: AXE), a leading developer of high-performance computing applications, today announced the adoption of the AxRecon image reconstruction solution for micro-computed tomography (CT) by a major pharmaceutical company. Eli Lilly, a leading developer of pharmaceutical products, has selected AxRecon™ solution to speed up image reconstruction times used in the pharmaceutical development process.
“Our early success in helping pharmaceutical companies reduce time spent in drug development is encouraging,” said Sean Krakiwsky, CEO of Acceleware Corp. “AxRecon’s ability to simply and seamlessly fit with existing CT scanner hardware and software to deliver results up to 50 times faster makes our product attractive to medical researchers and other users of CT Scanners.”
Pharmaceutical researchers regularly use CT Scanners in the drug development process to observe the effects of novel drug candidates on anatomy. However, deriving value from CT Scanners for drug development is hampered by slow image reconstruction time due to insufficient computing power. This reduces efficiency as well as the researcher’s ability to maximize the capabilities of advanced imaging equipment. Acceleware’s solution eliminates the computer processing bottleneck in image reconstruction workflow, and speeds up the evaluation of drug effectiveness.
Acceleware’s AxRecon works as a turn-key solution with a low cost of operation that fits into the current CT Scanner workflow, generating fully reconstructed, quality images completed hours sooner than before.
Acceleware’s application acceleration platform utilizes the power of NVIDIA® Graphic Processing Units (GPUs) to dramatically increase the speed of sophisticated computations, saving on power and space while maintaining image quality.
For more information about the AxRecon solution please visit our website at: www.acceleware.com.
Acceleware develops and markets solutions that enable software vendors to leverage heterogeneous, multi-core processing hardware without rewriting their applications for parallel computing. This acceleration middleware allows customers to speed-up simulation and data processing algorithms, benefiting from high performance computing technologies available in the market such as multiple-core CPUs, GPUs or other acceleration hardware.
Acceleware solutions are deployed by companies worldwide such Philips, Boston Scientific, Samsung, Eli Lilly, General Mills, Nokia, LG, RIM, Kyocera, Medtronic, Hitachi, Fujifilm, FDA, Mitsubishi, Sony Ericsson, AGC, NTT DoCoMo, and Renault to speed up product design, analyze data and make better business decisions in areas such as electronic manufacturing, oil & gas, medical and security imaging, industrial and consumer products, and academic research.
Acceleware is a public company on Canada's TSX Venture Exchange under the trading symbol AXE
The TSX Venture Exchange Inc. does not accept responsibility for the adequacy or accuracy of this release.